Book contents
- The Frith Prescribing Guidelines for People with Intellectual Disability
- Reviews
- The Frith Prescribing Guidelines for People with Intellectual Disability
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Acknowledgements
- Chapter 1 Intellectual Disability
- Chapter 2 Prescribing Practice
- Chapter 3 Physical Health Monitoring
- Chapter 4 Mental Health Conditions in People with Intellectual Disability
- Chapter 5 Trauma in People with Intellectual Disability
- Chapter 6 Anxiety Disorders
- Chapter 7 Depression
- Chapter 8 Bipolar Disorders
- Chapter 9 Schizophrenia
- Chapter 10 Aggression and Self-Injurious Behaviour
- Chapter 11 Personality Disorders
- Chapter 12 Sexual Offences and Paraphilias
- Chapter 13 Substance Use Disorders
- Chapter 14 Attention Deficit Hyperactivity Disorder
- Chapter 15 Autism
- Chapter 16 Sleep Disorders
- Chapter 17 Epilepsy
- Chapter 18 Dementia
- Chapter 19 Eating and Drinking Difficulties
- Chapter 20 Children and Adolescents
- Chapter 21 Prescribing for Health Issues in Women with Intellectual Disability
- Chapter 22 Older People
- Index
- References
Chapter 9 - Schizophrenia
Published online by Cambridge University Press: 07 November 2024
Book contents
- The Frith Prescribing Guidelines for People with Intellectual Disability
- Reviews
- The Frith Prescribing Guidelines for People with Intellectual Disability
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Acknowledgements
- Chapter 1 Intellectual Disability
- Chapter 2 Prescribing Practice
- Chapter 3 Physical Health Monitoring
- Chapter 4 Mental Health Conditions in People with Intellectual Disability
- Chapter 5 Trauma in People with Intellectual Disability
- Chapter 6 Anxiety Disorders
- Chapter 7 Depression
- Chapter 8 Bipolar Disorders
- Chapter 9 Schizophrenia
- Chapter 10 Aggression and Self-Injurious Behaviour
- Chapter 11 Personality Disorders
- Chapter 12 Sexual Offences and Paraphilias
- Chapter 13 Substance Use Disorders
- Chapter 14 Attention Deficit Hyperactivity Disorder
- Chapter 15 Autism
- Chapter 16 Sleep Disorders
- Chapter 17 Epilepsy
- Chapter 18 Dementia
- Chapter 19 Eating and Drinking Difficulties
- Chapter 20 Children and Adolescents
- Chapter 21 Prescribing for Health Issues in Women with Intellectual Disability
- Chapter 22 Older People
- Index
- References
Summary
The International Classification of Diseases ICD-11 describes a block called ‘Schizophrenia spectrum and other primary psychiatric disorders’ which includes schizophrenia, schizoaffective disorder, schizotypal disorder, acute and transient psychotic disorder, delusional disorder and other specified schizophrenias or other primary psychotic disorders. All these conditions are characterised by impaired assessment of reality and behaviour, delusions, hallucinations, disorganised thinking and behaviour, experiences of passivity and control, negative symptoms, and psychomotor disturbances. The ICD-11 specifies a symptom duration of at least one month and has removed the reliance on Schneiderian first-rank symptoms, giving equal weight to any hallucinations or delusion. Schizophrenia and other psychotic disorders form part of the group of severe mental illness. They can prove difficult to assess and treat in people with intellectual disability. The chapter presents an overview of the condition, the treatments with medication available, and their relevance.
Keywords
- Type
- Chapter
- Information
- Publisher: Cambridge University PressPrint publication year: 2024
References
Other Key Clinical Guidelines Referenced in This Chapter
National Institute for Health and Care Excellence (2014, Update 2021). Psychosis and schizophrenia in adults: Prevention and management (NICE Guideline CG178). National Institute for Health and Care Excellence. www.nice.org.uk/guidance/cg178.Google Scholar
National Institute for Clinical Excellence (2016) Mental health problems in people with learning disabilities: Prevention, assessment, and management (NG54). Published 14 September 2016. www.nice.org.uk/guidance/ng54/chapter/Recommendations.Google Scholar
Barnes, T. R., Drake, R., Paton, C., et al. (2020). Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 34(1), 3–78.CrossRefGoogle ScholarPubMed
Taylor, D. M., Barnes, T. R., & Young, A. H. (2021). The Maudsley prescribing guidelines in psychiatry. John Wiley & Sons.CrossRefGoogle Scholar
References
Aman, H., Naeem, F., Farooq, S., & Ayub, M. (2016). Prevalence of nonaffective psychosis in intellectually disabled clients: Systematic review and meta-analysis. Psychiatric Genetics, 26(4), 145–55. https://doi.org/10.1097/YPG.0000000000000137.CrossRefGoogle ScholarPubMed
American Psychiatric Association (2013). The Diagnostic and Statistical Manual of Mental Disorders (5th ed). American Psychiatric Association.Google Scholar
Antonacci, D. J. & de Groot, C. M. (2000). Clozapine treatment in a population of adults with mental retardation. Journal of Clinical Psychiatry, 61(1), 22–5.Google Scholar
Bakken, T. L. (2021). Behavioural equivalents of schizophrenia in people with intellectual disability and autism spectrum disorder. A selective review. International Journal of Developmental Disabilities, 67(5), 310–17. https://doi.org/10.1080/20473869.2021.1925402.CrossRefGoogle ScholarPubMed
Barabassy, A., Szatmári, B., Laszlovszky, I., et al. (2018) Negative symptoms of schizophrenia: Constructs, burden, and management. Psychotic disorders: An update. InTech. https://doi.org/10.5772/intechopen.73300.Google Scholar
Barrowcliff, A. L. (2008). Cognitive‐behavioural therapy for command hallucinations and intellectual disability: A case study. Journal of Applied Research in Intellectual Disabilities, 21(3), 236–45.CrossRefGoogle Scholar
Bhaumik, S., Tromans, S., Gumber, R. and Gangavati, S., 2020. Clinical assessment including bedside diagnosis. In Bhaumik, S, and Alexander, R (eds.). Oxford textbook of the psychiatry of intellectual disability, Oxford University Press, 7–22.CrossRefGoogle Scholar
Bokszanska, A., Martin, G., Vanstraelen, M., et al. (2003). Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study. International Clinical Psychopharmacology, 18(5), 285–91.Google ScholarPubMed
Cherry, K. E., Penn, D., Matson, J. L. & Bamburg, J. W. (2000). Characteristics of schizophrenia among persons with severe or profound mental retardation. Psychiatric Services, 51(7), 922–4.CrossRefGoogle ScholarPubMed
Cooper, S. A., Smiley, E., Morrison, J., et al. (2007). Psychosis and adults with intellectual disabilities. Prevalence, incidence, and related factors. Social psychiatry and psychiatric epidemiology, 42(7), 530–6. https://doi.org/10.1007/s00127-007-0197-9.CrossRefGoogle ScholarPubMed
Crowley, V., Rose, J., Smith, J., Hobster, K., & Ansell, E. (2008). Psycho-educational groups for people with a dual diagnosis of psychosis and mild intellectual disability: A preliminary study. Journal of Intellectual Disabilities, 12(1), 25–39.CrossRefGoogle ScholarPubMed
De Berardis, D., De Filippis, S., Masi, G., et al. (2021) Approach for a transitional model of early onset schizophrenia. Brain Sciences, 11(2), 275. https://doi.org/10.3390/brainsci11020275.CrossRefGoogle ScholarPubMed
Dosen, A., & Day, K. (2001) Epidemiology, aetiology and presentation of mental illness and behaviour disorders in persons with intellectual disabilities. In Dosen, A and Day, K. (eds.), Treating mental illness and behavior disorders in children and adults with intellectual disabilities, pp. 3–24. American Association Books.Google Scholar
Duggan, L., & Brylewski, J. (1999). Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: A systematic review. Journal of Intellectual Disability Research, 43(2), 94–104.CrossRefGoogle ScholarPubMed
Einfeld, S., Tonge, B., Chapman, L., et al. (2007) Inter‐rater reliability of the diagnoses of psychosis and depression in individuals with intellectual disabilities. Journal of Applied Research in Intellectual Disabilities, 20(5), 384–90.CrossRefGoogle ScholarPubMed
Escamilla, M. A. (2001). Diagnosis and treatment of mood disorders that co-occur with schizophrenia. Psychiatric Services, 52(7), 911–19.CrossRefGoogle ScholarPubMed
Fletcher, R., Loschen, E., Stavrakaki, C. & First, M. (2007). DM-ID: diagnostic manual – intellectual disability: A textbook of diagnosis of mental disorders in persons with intellectual disability. National Association for the Dually Diagnosed.Google Scholar
Foote, E. S. (1958) Combined chlorpromazine and reserpine in the treatment of chronic psychotics. Journal of Mental Science, 104(434), 201–5. https://doi.org/10.1192/bjp.104.434.201.CrossRefGoogle ScholarPubMed
Friedlander, R., Lazar, S., & Klancnik, J. (2001). Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. The Canadian Journal of Psychiatry, 46(8), 741–5.CrossRefGoogle Scholar
Gelly, F., Chambon, O. & Marie-Cardine, M. (1997). Long-term clinical experience with clozapine. L’encephale, 23(5), 385–96.Google ScholarPubMed
Ghaziuddin, M. (2005). Mental health aspects of Autism and Asperger syndrome. Jessica Kingsley Publishers.Google Scholar
Haddock, G., Lobban, F., Hatton, C., & Carson, R. (2004). Cognitive-behaviour therapy for people with psychosis and mild intellectual disabilities: A case series. Clinical Psychology & Psychotherapy: An International Journal of Theory & Practice, 11(4), 282–98.CrossRefGoogle Scholar
Hassiotis, A., & Sinai, A. (2009) Psychotic illness. In Hassiotis, A, Barron, D A, & Hall, I. (eds). Intellectual disability psychiatry: A practical handbook. Wiley, 67–83. https://doi.org/10.1002/9780470682968.CrossRefGoogle Scholar
Humphries, L., Michael, D., & Hassiotisc, A. (2020) Schizophrenia and related psychoses in people with intellectual disability. In Bhaumik, S. & Alexander, R. (eds.), Oxford textbook of the psychiatry of intellectual disability. Oxford University Press, 91–103.CrossRefGoogle Scholar
Hurley, A. D. (1996). The misdiagnosis of hallucinations and delusions in persons with mental retardation: A neurodevelopmental perspective. Seminars in Clinical Neuropsychiatry, 1, 122–33.Google ScholarPubMed
Institute of health Metrics and Evaluation (IHME) (2021). Global Health Data Exchange (GHDx). http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-permalink/27a7644e8ad28e739382d31e77589dd7.Google Scholar
Kamal, M., & Kelly, M. (1999). The use of clozapine in an individual with moderate intellectual disability, aggressive behaviour and resistant psychosis. Irish Journal of Psychological Medicine, 16(1), 32–3.CrossRefGoogle Scholar
Kirkland, J. (2005). Cognitive‐behaviour formulation for three men with learning disabilities who experience psychosis: How do we make it make sense? British Journal of Learning Disabilities, 33(4), 160–5.CrossRefGoogle Scholar
Korb, L., & Hassiotis, A. (2022). Psychotic disorders. In Bertelli, M. O. Deb, S., Munir, K., Hassiotis, A., & Salvador-Carulla, L. (eds.), Textbook of psychiatry for intellectual disability and autism spectrum disorder (pp. 537–55). Springer International Publishing.Google Scholar
Lainhart, J. E. (1999). Psychiatric problems in individuals with autism, their parents and siblings, International Review of Psychiatry, 11(4), 278–8, DOI: 10.1080/09540269974177.CrossRefGoogle Scholar
Laufer, N., Mozes, T., Hermesh, H., Weizman, A. & Frydman, M. (1999). Clinical characteristics of schizophrenia associated with velo-cardio-facial syndrome. Schizophrenia Research, 35(2), 105–12.Google Scholar
Lemay, K. R., Kogan, C. S., Rebello, T. J., et al. (2022). An international field study of the ICD-11 behavioural indicators for disorders of intellectual development. Journal of Intellectual Disability Research, 66(4), 376–91.CrossRefGoogle ScholarPubMed
Lindenmayer, J. P., & Kay, S. R. (1989). Depression, affect and negative symptoms in schizophrenia. The British Journal of Psychiatry, 155(S7), 108–14.CrossRefGoogle Scholar
Malfa, G. L., Lassi, S., Bertelli, M., & Castellani, A. (2006). Reviewing the use of antipsychotic drugs in people with intellectual disability. Human Psychopharmacology: Clinical and Experimental, 21(2), 73–89.CrossRefGoogle ScholarPubMed
Mason, J. & Scior, K., 2004. ‘Diagnostic overshadowing’ amongst clinicians working with people with intellectual disabilities in the UK. Journal of Applied Research in Intellectual Disabilities, 17(2), 85–90.CrossRefGoogle Scholar
National Institute for Health and Care Excellence (Great Britain). (2016). Mental health problems in people with learning disabilities: prevention, assessment and management (NG 54). National Institute for Health and Care Excellence.Google Scholar
NHS UK (2023). Causes – schizophrenia. 24 April. www.nhs.uk/mental-health/conditions/schizophrenia/causes/.Google Scholar
Oathamshaw, S. C., & Haddock, G. (2006). Do people with intellectual disabilities and psychosis have the cognitive skills required to undertake cognitive behavioural therapy? Journal of Applied Research in Intellectual Disabilities, 19(1), 35–46.CrossRefGoogle Scholar
Pankey, J., & Hayes, S. C. (2003). Acceptance and commitment therapy for psychosis. International Journal of Psychology and Psychological Therapy, 3(2), 311–28.Google Scholar
Ring, H., Zia, A., Lindeman, S., & Himlok, K., 2007. Interactions between seizure frequency, psychopathology, and severity of intellectual disability in a population with epilepsy and a learning disability. Epilepsy & Behavior, 11(1), 92–7.CrossRefGoogle Scholar
Royal College of Psychiatrists (2001). DC-LD: Diagnostic criteria for psychiatric disorders for use with adults with learning disabilities/mental retardation, London, Royal College of Psychiatrists, Occasional Paper OP 48.Google Scholar
Sajatovic, M., Ramirez, L. F., Kenny, J. T. & Meltzer, H. Y. (1994). The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients. Comprehensive Psychiatry, 35(1), 29–33.CrossRefGoogle ScholarPubMed
Sheehan, R., Hassiotis, A., Walters, K., et al. (2015). Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. British Medical Journal, 351. www.bmj.com/content/351/bmj.h4326.CrossRefGoogle Scholar
Sperner-Unterweger, B., Czeipek, I., Gaggl, S., Geissler, D., Spiel, G. & Fleischhacker, W. W. (1998). Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF): remission despite continuous treatment with clozapine. The British Journal of Psychiatry, 172(1), 82–4.CrossRefGoogle ScholarPubMed
Tantam, D. (2000). Adolescence and adulthood of individuals with Asperger syndrome. Asperger syndrome, 367–99.Google Scholar
Valle, R. (2020). La esquizofrenia en la CIE-11: comparación con la CIE-10 y el DSM-5/ Schizophrenia in ICD-11: Comparison of ICD-10 and DSM-5. Revista de psiquiatria y salud mental, 13(2), 95–104. https://doi.org/10.1016/j.rpsm.2020.01.001.CrossRefGoogle ScholarPubMed
Welch, K. A., Lawrie, S. M., Muir, W., & Johnstone, E. C. (2011). Systematic review of the clinical presentation of schizophrenia in intellectual disability. Journal of Psychopathology and Behavioral Assessment, 33, 246–53.CrossRefGoogle Scholar
Williams, H., Clarke, R., Bouras, N., Martin, J., & Holt, G. (2000). Use of the atypical antipsychotics olanzapine and risperidone in adults with intellectual disability. Journal of Intellectual Disability Research, 44(2), 164–9.CrossRefGoogle ScholarPubMed
World Health Organization (2019). International statistical classification of diseases and related health problems (11th ed.). https://icd.who.int/.Google Scholar
Zisook, S., McAdams, L. A., Kuck, J., et al. (1999). Depressive symptoms in schizophrenia. American Journal of Psychiatry, 156(11), 1736–43.CrossRefGoogle ScholarPubMed